Please use this identifier to cite or link to this item:
|Type:||Artigo de periódico|
|Title:||Immunoprophylaxis Of Superficial Bladder Cancer: A Prospective And Randomized Comparison Of Oral Versus Intravesical Bacillus Calmette-guerin.|
|Author:||Netto Júnior, N R|
Levi d'Ancona, C A
Claro, J F
|Abstract:||A total of 84 patients with superficial transitional cell carcinoma underwent transurethral resection of bladder tumor. All patients had stage pTa or pT1 transitional cell carcinoma or carcinoma in situ without other concurrent malignancies. The patients were assigned to three treatment groups: I. Control group-transurethral resection (TUR-BT) discontinued within the study. II. Oral BCG group-TUR-BT plus BCG (Moreau). III. Intravesical BCG group-TUR-BT plus BCG. Of 9 patients in the control group, 8 (89%) experienced tumor recurrence during a mean follow-up of 20 months. Of the 33 patients in the oral BCG group, 13 patients (39.3%) had recurrence during a mean follow-up of 39 months. Of the 42 patients in the intravesical group, 8 patients (19%) had recurrence in a 30-month mean follow-up. The incidence of complications was higher in the intravesical (33.4%) than in the oral BCG group (24.2%). These results showed that intravesical BCG is a more effective immunotherapy; however, oral BCG can be utilized in patients who do not accept intravesical BCG administration.|
Aged, 80 And Over
Carcinoma In Situ
Carcinoma, Transitional Cell
Neoplasm Recurrence, Local
Urinary Bladder Neoplasms
|Appears in Collections:||Artigos e Materiais de Revistas Científicas - Unicamp|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.